Table 3:
EASIX before conditioning therapy is a prognostic factor for OS and NRM after alloSCT the training cohort. 313 out of 755 patients died within the study. 743 patients were evaluable for the competing risk analysis of NRM and TTR, where 241 patients relapsed and 131 died in remission.
| A. Univariable analysis | OS | NRM | TTR | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p | CSHR | 95% CI | p | CSHR | 95% CI | p | |
| EASIX pre conditioning (2-fold change) | 1.14 | 1.06–1.23 | <0.001 | 1.23 | 1.10–1.38 | <0.001 | 1.02 | 0.93–1.11 | 0.744 |
| B. Multivariable analysis | OS | NRM | TTR | ||||||
| HR | 95% CI | p | CSHR | 95% CI | p | CSHR | 95% CI | p | |
| EASIX pre-conditioning (2-fold increase) | 1,09 | 1,01–1,18 | 0,033 | 1,21 | 1,07–1,36 | 0,002 | 0,98 | 0,90–1,08 | 0,738 |
| Age at alloSCT | 1,01 | 1,00–1,02 | 0,080 | 1,02 | 1,01–1,04 | 0,004 | 1,00 | 0,99–1,01 | 0,838 |
| Disease stage before alloSCT (EBMT Risk Score criteria)2 (high risk 2 vs. lower risk 0 or 1) | 1,78 | 1,41–2,25 | <0,001 | 1,18 | 0,82–1,69 | 0,363 | 2,06 | 1,58–2,69 | <0,001 |
| Donor (RD vs other) | 1,21 | 0,94–1,55 | 0,147 | 1,14 | 0,77–1,69 | 0,500 | 1,14 | 0,86–1,52 | 0,356 |
| Donor sex (male vs. female) | 1,03 | 0,81–1,31 | 0,822 | 0,82 | 0,57–1,18 | 0,279 | 1,13 | 0,85–1,50 | 0,388 |
| Recipient sex (male vs. female) | 1,02 | 0,81–1,30 | 0,840 | 1,09 | 0,75–1,58 | 0,636 | 0,95 | 0,72–1,24 | 0,688 |
| Conditioning (RIC vs. MAC) | 0,73 | 0,54–0,99 | 0,041 | 0,63 | 0,40–1,00 | 0,048 | 0,91 | 0,64–1,30 | 0,616 |
| Diagnosis (lymphoid vs myeloid) | 1,02 | 0,79–1,32 | 0,857 | 1,33 | 0,90–1,96 | 0,157 | 1,09 | 0,82–1,46 | 0,556 |
Abbreviations: OS: overall survival, NRM: non-relapse mortality, TTR: time to relapse, RD, related donor, RIC, reduced intensity conditioning, MAC: myeloablative conditioning, BM: bone marrow, PBSC: peripheral blood stem cells